Shares of Sophiris Bio Inc. (NASDAQ:SPHS) dropped 6.3% on Monday . The company traded as low as $4.60 and last traded at $4.73, with a volume of 1,200,152 shares changing hands. The stock had previously closed at $5.05.

SPHS has been the subject of a number of research reports. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of Sophiris Bio in a report on Friday, June 10th. Echelon Wealth Partners reissued a “buy” rating and issued a $5.00 price target on shares of Sophiris Bio in a report on Friday, June 10th.

The firm’s 50 day moving average price is $3.89 and its 200 day moving average price is $2.11. The company’s market capitalization is $94.47 million.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. On average, analysts predict that Sophiris Bio Inc. will post ($0.69) earnings per share for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.